Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2- breast cancer.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-02-06 DOI:10.1007/s12094-025-03856-7

João Queirós Coelho, Beatriz Lau, Rita Pichel, Laura Guerra, Hugo Miranda, Raquel Romão, Maria João Sousa, Fernando Gonçalves, Joana Simões, Sérgio Xavier Azevedo, António Araújo

{"title":"Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2- breast cancer.","authors":"João Queirós Coelho, Beatriz Lau, Rita Pichel, Laura Guerra, Hugo Miranda, Raquel Romão, Maria João Sousa, Fernando Gonçalves, Joana Simões, Sérgio Xavier Azevedo, António Araújo","doi":"10.1007/s12094-025-03856-7","DOIUrl":null,"url":null,"abstract":"Introduction: Neoadjuvant chemotherapy (NACT) is a treatment option for early-stage hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer. Despite its use, pathological response rates in this subtype are often lower, and the impact of individual risk factors remains unclear. This study aimed to identify biomarkers and create a predictive score for NACT response.Methods: This retrospective, single-center study included patients with stage IIA-IIIC HR + /HER2- breast cancer treated with NACT and surgery (2019-2023). Multiple logistic regression analyzed associations between clinicopathological variables and pathologic response (partial/complete vs. absent) (p < 0.05). The best-performing model was used to develop a risk score.Results: The study included 101 patients. Significant predictors of pathological response included tumor grade (G2/3 vs. G1), menopausal status (pre- vs. post-menopausal), and intrinsic subtype (luminal B vs. A).Conclusions: A dynamic calculator was created incorporating grade, hormonal status, intrinsic subtype, and Ki-67. This tool provides real-time input, facilitating personalized therapeutic decision-making.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03856-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Neoadjuvant chemotherapy (NACT) is a treatment option for early-stage hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer. Despite its use, pathological response rates in this subtype are often lower, and the impact of individual risk factors remains unclear. This study aimed to identify biomarkers and create a predictive score for NACT response.

Methods: This retrospective, single-center study included patients with stage IIA-IIIC HR + /HER2- breast cancer treated with NACT and surgery (2019-2023). Multiple logistic regression analyzed associations between clinicopathological variables and pathologic response (partial/complete vs. absent) (p < 0.05). The best-performing model was used to develop a risk score.

Results: The study included 101 patients. Significant predictors of pathological response included tumor grade (G2/3 vs. G1), menopausal status (pre- vs. post-menopausal), and intrinsic subtype (luminal B vs. A).

Conclusions: A dynamic calculator was created incorporating grade, hormonal status, intrinsic subtype, and Ki-67. This tool provides real-time input, facilitating personalized therapeutic decision-making.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.